Hypertensive renal vascular disease and cardiovascular endpoints

Current Opinion in Cardiology

Volumn 21, Issue 4, 2006, Pages 305-309

  Matavelli, Luis C ^a   Zhou, Xiaoyan ^a   Frohlich, Edward D ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Albuminuria; Cardiovascular disease; Hypertension; Renal function

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; ERYTHROPOIETIN;

ANEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE EXACERBATION; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; KIDNEY DYSFUNCTION; MICROALBUMINURIA; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RENOVASCULAR DISEASE; RENOVASCULAR HYPERTENSION; REVIEW; URIC ACID NEPHROPATHY;

ALBUMINURIA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DISEASE PROGRESSION; ERYTHROPOIETIN; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; HYPERURICEMIA; KIDNEY FAILURE; NATRIURETIC PEPTIDE, BRAIN; URIC ACID;

EID: 33748131696     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000231399.02481.de     Document Type: Review

References (65)

1. Frohlich ED. Recent advances in hypertension, stroke, and cardiorenal disease. Curr Opin Cardiol 2005; 20:258-263.
2. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37:1053-1059.
3. Frohlich ED. Target organ involvement in hypertension: a realistic promise of prevention and reversal. Med Clin North Am 2004; 88:209-221.
4. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003; 108:2154-2169.
5. Anavekar NS, Pfeffer MA. Cardiovascular risk in chronic kidney disease. Kidney Int 2004; 66 (Suppl. 92):S11-S15.
6. Go AS, Chertow GM, Dongjie F, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
7. McClellan WM, Langston RD, Presley R. Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol 2004; 15:1912-1919.
8. Menon V, Gul A, Sarnak MJ. Cardiovascular risk factors in chronic kidney disease. Kidney Int 2005; 68:1413-1418.
9. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2005; 45:198-202. Important sub-study from the LIFE study showing that a reduction in albuminuria in hypertensive patients during treatment was associated with a decreased incidence of CVD, suggesting a direct relationship between reduction of albuminuria and regression of hypertensive vascular disease. It is clear, however, that this reduction in albumin resulted in an amelioration of hypertensive renal vascular disease.
10. Kobrin I, Frohlich ED, Ventura HO, Messerli FH. Renal involvement follows cardiac enlargement in essential hypertension. Arch Intern Med 1986; 146:272-276.
11. Fesler P, du Cailar G, Ribstein J, Mimran A. Heterogeneity of cardiorenal characteristics in normotensive subjects. Hypertension 2004; 43:219-223.
12. Verdecchia P, Reboldi GP. Hypertension and microalbuminuria: the new detrimental duo. Blood Pressure 2004; 13:198-211.
13. Watchell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139:901-906.
14. Preston E, Ellis MR, Kulinskaya E, et al. Association between carotid artery intima-media thickness and cardiovascular risk in CKD. Am J Kidney Dis 2005; 46:856-862.
15. Mann JF, Yi QL, Gerstein HC. Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney Int 2004; 66 (Suppl. 92):S59-S62.
16. The Seventh Report of the Joint National, Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289:2560-2572.
17. Guidelines Committee: 2003 European Society, of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
18. Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals. The Framingham Heart Study. Circulation 2005; 112:969-975. This study supports the concept that lower levels of albuminuria, even below the cut-off point for microalbuminuria, are associated with an increased incidence of cardiovascular events and death in non-hypertensive, non-diabetic individuals.
19. Wang TJ, Evans JC, Meigs JB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005; 111:1370-1376. An important study showing that non-hypertensive individuals with higher levels of albuminuria had a higher risk for the development and progression of hypertension.
20. Ruilope LM. Renal function and cardiovascular risk in hypertensive patients. J Hypertens 2005; 23:1787-1788.
21. Bakris GL. Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep 2004; 6:352-356.
22. Frohlich ED, Varagic J. The role of sodium in hypertension is more complex than simply elevating arterial pressure. Nat Clin Pract Cardiovasc Med 2004; 1:24-30.
23. Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 2000; 35 (Suppl. 1):S97-S105.
24. Culleton BF, Larson MG, Parfrey PS, et al. Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am J Med 2000; 109:1-8.
25. Yu HT. Progression of chronic renal failure. Arch Intern Med 2003; 163:1429-1471.
26. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (Suppl. 1):S1-S266.
27. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164:659-663.
28. Mann JFE, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134:629-636.
29. Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12:218-225.
30. Coresh J, Astor B, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41:1-12.
31. Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia. The Third National Health and Nutrition Examination Survey. Arch Intern Med 2002; 162:1401-1408.
32. Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: A review of the current state of knowledge. Kidney Int 2002; 80:S35-S38.
33. Weiner DE, Tighiouart H, Vlagopoulos PT, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 2005; 16:1803-1810. This study analyzed data from four community-based studies showing a synergistic adverse outcome effects on the heart with association of both LVH and anemia in the presence of CKD.
34. Rao M, Pereira BJG. Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int 2005; 68:1432-1438.
35. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283:2404-2410.
36. Frohlich ED. Uric acid: a risk factor for coronary heart disease. JAMA 1993; 270:378-379.
37. Messerli FH, Frohlich ED, Dreslinski GR, et al. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93:817-821.
38. Nunez BD, Frohlich ED, Garavaglia GE, et al. Serum uric acid in renovascular hypertension: reduction following surgical correction. Am J Med Sci 1987; 294:419-422.
39. Frohlich ED, Arthur C. Corcoran Memorial Lecture: influence of nitric oxide and angiotensin II on renal involvement in hypertension. Hypertension 1997; 29:188-193.
40. Zhou X, Ono H, Ono Y, Frohlich ED. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol 2004; 24:242-249.
41. Zhou X, Matavelli LC, Ono H, Frohlich ED. Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR. Am J Physiol Renal Physiol 2005; 289:F871-F879.
42. Zhou X, Matavelli LC, Frohlich ED. Uric acid: its relationship to renal hemodynamics and the renal renin-angiotensin system. Curr Hypertens Rep 2006; 8:120-124. This review paper analyzes the most recent data relating hyperuricemia and hypertension, emphasizing the progression of renal vascular involvement in hypertension as a determining factor in the development of hyperuricemia.
43. Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67:237-247.
44. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005; 45:18-20.
45. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003; 169:203-214.
46. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351:2599-2610.
47. Stuveling EM, Bakker JL, Hillege HL, et al. C-reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension 2004; 43:791-796.
48. Knight EL, Rimm EB, Pai JK, et al. Kidney dysfunction, inflammation, and coronary events: a prospective study. J Am Soc Nephrol 2004; 15:1897-1903.
49. Menon V, Greene T, Wang X, et al. C-reactive protein and albumin as predictors of all cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68:766-772.
50. Mehra MR, Uber PA, Potluri S, et al. Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. Am J Cardiol 2004; 94:454-458.
51. Pedersen F, Raymond I, Kistorp C, et al. N-terminal pro-brain natriuretic peptide in arterial hypertension: a valuable prognostic marker of cardiovascular events. J Card Fail 2005; 11 (Suppl 5):S70-S75.
52. Silver MA. The natriuretic peptide system: kidney and cardiovascular effects. Curr Opin Nephrol Hypertens 2006; 15:14-21. Important review paper that discusses the metabolism and physiological effects of the natriuretic peptides in the kidney and in the cardiovascular system affecting hypertension.
53. Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005; 46:610-620.
54. van der Zander K, Houben AJHM, Hroon AA, et al. Does brain natriuretic peptide have a direct renal effect in human hypertensives? Hypertension 2003; 41:119-123.
55. Frohlich ED. Left ventricular hypertrophy: a "factor of risk": mass is reversible, but is the risk? J Am Coll Cardiol 2004; 43:2216-2218.
56. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001; 12:1079-1084.
57. McMahon LP, Roger SD, Levin A. Development, prevention, and potential reversal of left ventricular hypertrophy in chronic renal disease. J Am Soc Nephrol 2004; 15:1640-1647.
58. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15:1307-1315.
59. Fesler P, Ribstein J, du Cailar G, Mimran A. Determinants of cardiorenal damage progression in normotensive and never-treated hypertensive subjects. Kidney Int 2005; 67:1974-1979. Important longitudinal clinical study in which determinants of cardiorenal damage progression were defined in normotensive subjects and in patients with essential hypertension, showing that baseline blood pressure and the progression of blood pressure during the follow-up were the main determinants of the decline in GFR, progression of albuminuria, and LVH.
60. McCullough PA. Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. Curr Opin Nephrol Hypertens 2004; 13:591-600.
61. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285-1295.
62. Muntner P, He J, Astor BC, et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2005; 16:529-538.
63. Kramer H, Jacobs DR, Bild D, et al. Urine albumin excretion and subclinical cardiovascular disease. The Multi-Ethnic Study of Atherosclerosis. Hypertension 2005; 46:38-43.
64. de Leeuw PW, Ruilope LM, Palmer CR, et al. Clinical significance of renal function in hypertensive patients at high risk. Arch Intern Med 2004; 164:2459-2464.
65. Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62:1402-1407.